Our Trustees

Cancer Research UK, a company limited by guarantee and a registered charity, is governed by a Council of Trustees, the Charity’s board of directors.

Council’s role is to set the Charity’s strategic direction, monitor the delivery of the Charity’s objects, uphold its values and governance and guide, advise and support the Chief Executive, who leads the Senior Management Team towards achieving the Charity’s vision and purpose.

The Council of Trustees is led by the Chair, Professor Sir Leszek Borysiewicz.

Our Trustees' Register of Interests is available upon request from the Company Secretary (secretariat@cancer.org.uk). Please see the link on the right to download our Articles of Association.


Professor Sir Leszek Borysiewicz FRS MA PhD FRCP FMedSci (Chair)

Appointed 2016. Sir Leszek was appointed as a Trustee in July 2016 and as Chair in November 2016. Following a distinguished academic and clinical research career and prior to his appointment as Vice-Chancellor at the University of Cambridge in 2010, Sir Leszek’s roles included Chief Executive of the Medical Research Council and Deputy Rector of Imperial College London. He was also a founding Fellow of the Academy of Medical Sciences. His work in vaccines included Europe’s first trial of a therapeutic vaccine for human papillomavirus to treat cervical cancer, research conducted at the University of Cardiff and funded by Cancer Research UK. He also serves on the board of UKRI, the governing board of The Courtauld Institute of Art and on the Council of the Royal Society.

He was knighted in 2001 for his pioneering work in vaccines.


Carolyn Bradley MA (Cantab) (Deputy Chair)

Appointed 2015. Carolyn has extensive marketing and commercial experience from her executive career with Tesco, where her roles included Group Brand Director, UK Marketing Director, and Chief Operating Officer for Tesco.com. She is now a non-executive Director of Marston’s plc, SSP Group pls, B&M Value Retail S.A.,Majid Al Futtaim Retail LLC and The Mentoring Foundation. In addition she is a member of the Advisory Board for the Cambridge Judge Business School. Carolyn graduated from Cambridge University before joining Tesco, where she led many innovations such as the Clubcard loyalty scheme, the ‘Every Little Helps’ service campaign and the grocery home delivery business. Carolyn has also been a Trustee for the DrinkAware Trust.


Catherine Brown LLB (Hons)

Appointed 2015. Catherine has broad experience in strategy and organisational change, having previously been Group Strategy Director of Lloyds Banking Group, Executive Director HR of the Bank of England, and Chief Operating Officer of Apax Partners. Catherine was a non-executive board member of the Cabinet Office until March 2020.  She is a trustee of Chatham House and the Royal Institute of International Affairs. She sits on the board of FNZ (UK), a private equity backed financial services technology company, and is Chair of Additive Flow Ltd, a manufacturer of low cost 3D printers utilising recycled plastic. She is a trustee of Blue Cross and also has charity projects across the Himalayan region. She spent her early career as a banker before joining McKinsey and subsequently ran her own management consultancy for five years before moving into private equity at Apax Partners.


Peter Chambré

Appointed 2016. Peter is Chair of Cancer Research Technology Ltd, the commercialisation arm of Cancer Research UK and Immatics Biotechnologies, a company developing new cancer immunotherapy treatments.  He is a director of UDG Healthcare plc. He was Chief Executive Officer of Cambridge Antibody Technology plc from 2002 until its acquisition by AstraZeneca in July 2006.


Tracy De Groose LLB

Appointed 2018. Tracy is Executive Chair of Newsworks and of The Ozone Project, Chair of Beached Ltd., advisor and investor. At Newsworks, the marketing arm of the national newsbrands, she is tasked with championing Britain's vibrant news media to readers and advertisers across the nation. Prior to this, Tracy was CEO of Dentsu Aegis Network, where she managed the UK & Ireland P&L of 20 media, creative, digital and data agency businesses with over 4,000 people across London, Manchester, Edinburgh and Dublin. Under her leadership the Group doubled in size between May 2014 and September 2017. A champion of WACL and a trailblazer for diversity and inclusion, Tracy believes in paving the way for others to follow and regularly prioritises time to mentor, support and guide emerging talent. In 2016 she was named one of London's most influential people in the Evening Standard's Progress 1000 list and hailed as a ‘Woman to Watch Europe’ by Advertising Age.


Dr Robert Easton BSc ARCS DPhil FCGI

Appointed 2020. Dr Robert Easton is a former Partner of Carlyle, the global alternative asset management company. During his 19 years at the firm he performed a number of roles, as an investment professional, being a fund head in buyout and technology investing, while serving on multiple portfolio company boards.

Robert is a past Chairman of the British Venture Capital Association and a serial investor in technology driven, small and start-up businesses. He has had a variety of engagements with the higher education sector at Oxford University, where until recently he was a Pro-Vice-Chancellor, as well as at Imperial College, London. In addition to being a Trustee at CRUK, Robert is a Fellow of the British Heart Foundation, and a Trustee of the Young Vic Theare and funds causes in science, sport, music, higher education, conservation and sub-Saharan Africa.


Professor Dame Amanda Fisher DBE FRS FMedSci

Appointed 2017. Professor Fisher is Director of the Medical Research Council London Institute of Medical Sciences (MRC LMS) and jointly runs the MRC LMS's Lymphocyte Development Group. She is also Head of the Institute of Clinical Sciences at Imperial College London’s Hammersmith Campus. She obtained her PhD from the University of Birmingham and studied retrovirus biology at the National Institutes of Health, USA, where she helped isolate and characterise the first molecular clones of HIV. In 1993 she established a research team at the newly formed Clinical Sciences Centre in London (now LMS). Her research group study fundamental aspects of cell commitment including nuclear organisation, gene regulation and chromatin structure. She was awarded the EMBO Gold medal in 2002 and was elected a Fellow of the Royal Society in 2014.

In the New Year’s Honours 2017 she was made a Dame Commander of the Order of the British Empire for “services to medical research and the public understanding of science”.


Professor Sir Stephen T Holgate CBE FMedSci

Appointed 2014. Professor Holgate is Medical Research Council Clinical Professor of Immunopharmacology at the Faculty of Medicine in Southampton. Over 35 years he has studied asthma and related illnesses using a range of scientific approaches including epidemiology, pathology and immunology, pharmacology, experimental medicine and genetics with a strong translational emphasis. Professor Holgate advises the UK Government and EU on issues relating to Medical Research and Air Pollution and Chemical Hazards. He is a member f the Natural Environment Research Council, the Governing Board of the Nuffield Council on Bioethics and Trustee of the Great Ormond Street Hospital Children's Charity and the Kennedy Trust for Rheumatology Research.  In 2019 Stephen was appointed as the UKRI Clean Air Champion.

He was appointed Commander of the Order of the British Empire (CBE) in the 2011 Queen’s New Year’s Honours and awarded a Knighthood in the 2020 Queen's Birthday Honours.


Professor Nic Jones PhD FMedSci

Appointed 2020. Nic is currently Director of Strategic Initiatives at the Manchester Cancer Research Centre (MCRC), a partnership between Cancer Research UK, the Christie NHS Foundation Trust and the University of Manchester. He was Director of the MCRC for 12 years from its inception in 2006 and oversaw its development into one of the foremost comprehensive cancer centres in Europe. In addition, from 2011-2016, Nic was the CRUK Chief Scientist with responsibility for overseeing the scientific strategy of the organisation. Nic was also previously the Director of the CRUK Manchester Institute and led a research team investigating specific signalling pathways implicated in cancer development and growth.


Professor Pamela Kearns PhD FRCPCH

Appointed 2021. Professor Pam Kearns is Chair of Clinical Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham Women and Children’s Hospital.  She is Director of the University of Birmingham’s Institute of Cancer and Genomic Sciences and Director of the Cancer Research UK Clinical Trials Unit (CRCTU).  As Director of CRCTU, she leads the research strategy for one of UK's largest cancer trials unit, delivering a trials portfolio of over 100 multi-centre & international cancer trials for a wide range of cancers, occurring in all children, young people and adults. 

She was elected President of the European Society of Paediatric Oncology (SIOP Europe) in 2019, having been a Board member since 2013. She has several European roles including Executive Board Member of the academic consortium ‘Innovative Therapeutics in Childhood Cancer’ (ITCC), Chair of ITCC’s European Sponsor Institutions Committee and Steering Committee member of the International multi-stakeholder platform ‘ACCELERATE’. Her research interests are focussed of drug development and innovation of design and delivery of clinical trials for childhood cancers. She was also a Senior Clinical Advisor to Cancer Research UK from 2015 to 2020 and is a Trustee of a Child of Mine, a charity dedicated to supporting bereaved parents.


David Lindsell

Appointed 2014. David is a chartered accountant and has been a non-Executive Director and Audit Committee Chair of three listed companies since 2007, prior to which he was a Partner at Ernst & Young where he served as the lead audit Partner for numerous FTSE 100 companies and was a member of the firm’s governing council for many years. He is Deputy Chair of Governors at The University of the Arts London and was Deputy Chair of the Financial Reporting Review Panel from 2008 to 2012.


Andrew Palmer FCA (Treasurer)

Appointed 2014. Andrew was formerly Group Finance Director of Legal & General plc where he had also held a number of financial and operational roles in the asset management, insurance and international businesses. Until April 2013 Andrew had been Senior Independent Director of SEGRO, the Industrial REIT. He was a non-executive Director and Chair of the Audit Committee at Royal London Group plc until March 2020 and a non-executive Director and Chair of the Audit Committee at Direct Line Group plc until May 2018. Andrew is also a panel member of the Financial Reporting Review Panel of the Financial Reporting Council and is a Trustee and Treasurer of the Royal School of Needlework. He is a Fellow of the Institute of Chartered Accountants in England and Wales.


Professor Sir Bruce Ponder FRCP FMedSci FRS

Appointed 2015. Bruce Ponder is Emeritus Professor of Oncology at Cambridge and a Senior Group Leader in the Cancer Research UK Cambridge Institute. He was formerly Li Ka Shing Professor of Oncology, Founding Director of the Cancer Research UK Cambridge Research Institute and of the Cambridge Cancer Centre, and co-Director of both the Hutchison/MRC Research Centre and of the Strangeways Research Laboratories for Genetic Epidemiology. Bruce Ponder trained in internal medicine in London, and then did his PhD at ICRF (now the Francis Crick Institute). He trained in Medical Oncology at the Dana Farber Cancer Institute, Harvard University. His clinical and research career was in the genetics of susceptibility to cancer. Over the past 20 years he has led the development of a new laboratory and clinical centre for cancer research in Cambridge. Milestones have been the establishment of the Strangeways Laboratories for Genetic Epidemiology in 1997, the Hutchison/MRC Research Centre in 2001, the CRUK Cambridge Institute in 2007, and the designation of Cambridge as a CRUK Major Cancer Centre in 2015.

He was knighted in 2008 for ‘services to medicine’.


Professor Sir Mike Richards CBE MD FRCP FRCR (Hon) FRCPath (Hon) FRCSEd (Hon)

Appointed 2017. Sir Mike Richards was appointed the First Chief Inspector of Hospitals for England at the Care Quality Commission (CQC) in July 2013. He retired in July 2017. He was Director for Reducing Premature Mortality at NHS England (2012-13) and National Cancer Director at the Department of Health (1999-2013). Prior to these appointments he was a consultant and reader in Medical Oncology at Guy’s and St Thomas’ NHS Trust (1986-1995) and Professor of Palliative Medicine (1995-1999).

He was appointed CBE in 2001 and Knight Batchelor in 2010 for ‘services to medicine’.


Joanne Shaw

Appointed 2020. Joanne is a qualified Accountant with a broad commercial, public and third sector background. As past Chair of NHS Direct, she has a particular interest in the use of mobile and digital channels for health and medicine, and the changing relationship between individuals, their own health and their health care providers. She is currently a director of Vitality, the shared value insurance provider. She has chaired the Audit and Risk Committees of NHS England, the National Audit Office, and the Money Advice Service. Past non-executive positions include Deputy Chair of Nuffield Health and Chair of the British Equestrian Federation.



Professor Moira Whyte OBE PhD FRCP FRCPE FMedSci FRSE

Appointed 2020. Professor Moira Whyte is Vice-Principal and Head of the College of Medicine and Veterinary Medicine and the Sir John Crofton Professor of Respiratory Medicine at the University of Edinburgh. She was formerly Director of the MRC/University of Edinburgh Centre for Inflammation Research and Head of Edinburgh Medical School. She is a member of MRC Strategy Board and Chair of the MRC Training and Careers Group and is also Chair of Sub-panel 1 (Clinical Medicine) for the UK’s Research Excellence Framework (REF)2021. Her research interests are in basic mechanisms of innate immunity in the context of chronic lung diseases.


Get in touch

If you require further information or have any comments please get in touch.

020 7242 0200

Contact us